23 Feb Avery Therapeutics

Posted at 18:45h in by brady

Jordan Lancaster, Ph.D., CEO

Oct. 8 | 1:30pm | FLW Ballroom G

Tucson, AZ

(Private)

Avery Therapeutics is a late-stage pre-clinical company developing a new class of restorative medicine for patients with intractable diseases of inflammation and fibrosis by levering the therapeutic potential within the immune system. Avery’s lead clinical candidate AT-102 uses our proprietary MPhase biologic platform to address heart failure, one of the leading causes of death in the world. In pre-clinical models, AT-102 structures the heart to improve and establishes best-in-class efficacy.

www.averythera.com

About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 2,000 attendees – over 20% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 6-8, 2025
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions